Clinical Trials › NCT05906992
RecruitingPhase 3
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Sponsored by Celltrion
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 512
Target enrollment
Jan 2024
Start date
Jan 2029
Expected completion
Interventions / Treatments
CT-P53US-OcrevusEU-Ocrevus
Conditions studied
Relapsing-remitting Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.